Last reviewed · How we verify

PH HEALTH — Portfolio Competitive Intelligence Brief

PH HEALTH pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ryanodex DANTROLENE marketed Skeletal Muscle Relaxant Ryanodine receptor 1 Metabolic 1974-01-01
Coly-Mycin M COLISTIMETHATE SODIUM marketed Polymyxin-class Antibacterial Metabolic 1970-01-01
Ketalar ketamine marketed General Anesthetic Glutamate [NMDA] receptor Metabolic 1970-01-01
Brevital Sodium METHOHEXITAL marketed Barbiturate GABA-A receptor alpha-1/beta-3/gamma-2 Metabolic 1960-01-01
Delestrogen ESTRADIOL VALERATE marketed Estrogen Estrogen receptor Oncology 1954-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Ajou University School of Medicine · 1 shared drug class
  3. Apil · 1 shared drug class
  4. Baxter · 1 shared drug class
  5. Kamuzu University of Health Sciences · 1 shared drug class
  6. Mayne Pharma · 1 shared drug class
  7. Merck & Co. · 1 shared drug class
  8. Pfizer Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PH HEALTH:

Cite this brief

Drug Landscape (2026). PH HEALTH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ph-health. Accessed 2026-06-10.

Related